10-K: ATI Physical Therapy Details Securities in 10-K Filing, Outlines Share Structure and Warrant Terms

Sentiment:

Annual Results


ATI Physical Therapy's 10-K filing provides a detailed overview of its registered securities, including common stock, warrants, and preferred stock, along with key dates and terms.

Capital raiseThe document details the terms of convertible notes that could be converted into common stock, potentially raising capital for the company.The company has the ability to redeem warrants for cash or common stock, which could impact its cash position and capital structure.The company has a delayed draw right to issue an additional $25 million of convertible notes.

Summary

  • ATI Physical Therapy's 10-K filing describes the company's registered securities, which include Class A common stock and redeemable warrants.
  • The document also details unregistered securities such as 2022 Warrants, Private Placement Warrants, Series A and B Preferred Stock, and Notes, explaining how their terms may affect common stock and public warrant holders.
  • A one-for-50 reverse stock split of the common stock was executed on June 14, 2023, which proportionally adjusted the exercise prices and number of shares for all stock options, warrants, and vesting shares.
  • The company's authorized capital stock consists of 450 million shares of common stock, 20 million shares of Class F common stock, and 1 million shares of preferred stock, with 165,000 shares designated as Series A and 450,000 as Series B preferred stock.
  • Holders of common stock have one vote per share and are entitled to dividends and distributions as declared by the board, subject to the rights of preferred stockholders.
  • Series A Preferred Stock has a 12% annual dividend rate, which compounds if not paid in cash, and ranks senior to common stock but junior to the company's debt.
  • Series B Preferred Stock has no dividend or redemption rights but has full voting rights equal to common stock, with voting power based on an as-converted basis at an initial price of $12.87 per share.
  • The company has four series of outstanding warrants: Public Warrants, Private Placement Warrants, Series I Warrants, and Series II Warrants, each with different exercise prices and terms.
  • Public Warrants are exercisable at $575 per share and can be redeemed for $0.01 per warrant under certain conditions, or for common stock based on a table tied to the stock price and time to expiration.
  • Private Placement Warrants are similar to Public Warrants but are not redeemable while held by the sponsor and can be exercised on a cashless basis.
  • Convertible notes issued in 2023 bear an 8% interest rate, payable in-kind, and can be converted into common stock at an initial price of $12.50 per share.
  • The document also outlines anti-takeover provisions, including the elimination of a classified board structure, and exclusive forum provisions for legal proceedings.

Sentiment

Score: 5

Explanation: The document is neutral in tone, providing factual information about the company's securities. It does not express any positive or negative sentiment about the company's future prospects.

Positives

  • The document provides a comprehensive overview of the company's capital structure.
  • The reverse stock split was completed to improve the share price.
  • The company has the ability to redeem warrants for cash or common stock, providing flexibility in capital management.
  • The convertible notes provide a potential source of equity capital in the future.

Negatives

  • The high exercise price of the Public Warrants ($575 per share) may make them less attractive to holders.
  • The Series B Preferred Stock has no dividend or redemption rights, which may be unattractive to some investors.
  • The company has significant anti-takeover provisions, which may limit shareholder rights.
  • The company has a complex capital structure with multiple classes of securities.

Risks

  • The high exercise price of the Public Warrants may make them less attractive to holders.
  • The Series B Preferred Stock has no dividend or redemption rights, which may be unattractive to some investors.
  • The company has significant anti-takeover provisions, which may limit shareholder rights.
  • The company has a complex capital structure with multiple classes of securities.
  • The company's ability to redeem warrants for cash or common stock is subject to certain conditions.
  • The company's ability to convert notes into common stock is subject to certain conditions.

Future Outlook

The document does not contain specific forward-looking statements about the company's future financial performance, but it does outline the terms and conditions of various securities that could impact the company's capital structure and future financing options.

Industry Context

This document is a standard securities disclosure, and its content is specific to ATI Physical Therapy. It does not directly relate to broader industry trends, but it does provide insight into the company's financial structure and potential future capital raising activities.

Comparison to Industry Standards

  • The use of warrants and convertible notes is a common practice for companies seeking to raise capital, particularly in the healthcare sector.
  • The terms of the warrants and convertible notes are specific to ATI Physical Therapy and may not be directly comparable to other companies.
  • The reverse stock split is a common strategy for companies seeking to maintain listing requirements or improve their share price.
  • The anti-takeover provisions are common in corporate charters and bylaws, but the specific terms may vary from company to company.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Board StructureThe company eliminated the classified structure of the Board and will transition to annual election of all directors by 2025.June 2023This change may make the company more susceptible to shareholder influence.
BylawsThe company's bylaws prohibit stockholder action by written consent and limit the ability of stockholders to call a special meeting.June 2023These changes may make it more difficult for shareholders to influence company decisions.

Legal Proceedings

  • The document outlines exclusive forum provisions for legal proceedings, requiring certain actions to be brought in the Court of Chancery of the State of Delaware.

Stakeholder Impact

  • Shareholders may experience dilution if convertible notes are converted into common stock or if additional shares are issued.
  • Warrant holders may benefit from the potential for appreciation in the company's stock price.
  • Creditors may be impacted by the company's ability to repay its debt obligations.
  • Employees may be impacted by changes in the company's capital structure and financial performance.

Next Steps

  • The company may redeem warrants for cash or common stock.
  • Holders of convertible notes may choose to convert them into common stock.
  • The company may issue additional shares of common stock in the future.
  • The company may seek additional financing through debt or equity offerings.

Key Dates

DateDescription
February 21, 2021Date of the Amended and Restated Registration Rights Agreement.
February 24, 2022Date of the IPO Warrant Agreement and 2022 Warrant Agreement.
February 24, 2022Date of the Investors Rights Agreement.
February 24, 2022Date of the Purchase Agreement.
February 24, 2022Date of the First Amended and Restated Certificate of Designation for the Series A Preferred Stock.
April 17, 2023Date of the Second Lien Note Purchase Agreement.
June 14, 2023Date of the one-for-50 reverse stock split.
June 15, 2023Date of the Registration Rights Agreement.
June 15, 2023Date of the First Amendment to Note Purchase Agreement.

Keywords

common stock, warrants, preferred stock, reverse stock split, convertible notes, securities, capital structure, redemption, voting rights, anti-takeover

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.